Literature DB >> 7773869

Papillon-Lefèvre syndrome associated early onset periodontitis: a review and case study.

D French1, H Scott, C M Overall.   

Abstract

A case of Papillon-Lefèvre syndrome that has been managed successfully for six years is reported. Papillon-Lefèvre syndrome is a rare form of early onset periodontitis that occurs at a rate of 1-3 per million. Diagnostic features include palmar-plantar hyperkeratosis and rapid periodontal destruction. Although the etiology of this syndrome is unknown, current theories on the nature of the underlying defect fall into three main categories: anatomical, bacterial and host response. Historically, Papillon-Lefèvre syndrome was thought to lead to the inevitable loss of both the primary and permanent dentitions. However, a recently proposed treatment involving antibiotic coverage, extraction of the primary dentition and a period of edentulism has been shown to be effective in maintaining the permanent dentition. Since treatment may begin prior to the eruption of the permanent dentition, early recognition of Papillon-Lefèvre syndrome is critical. Any young patient who exhibits palmar hyperkeratosis should be examined carefully for periodontal breakdown. Since the number of cases available for study is limited, referral of such individuals to University dental clinics may allow for a more specific analysis of immune or bacterial factors that may lead to a better understanding of this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773869

Source DB:  PubMed          Journal:  J Can Dent Assoc        ISSN: 0709-8936            Impact factor:   1.316


  2 in total

1.  A Rare Presentation of Psychotic Depression with Suicidality in a Case of Papillon-Lefèvre Syndrome.

Authors:  Anand Lingeswaran; S Devakumari Gopal
Journal:  Indian J Psychol Med       Date:  2018 Jul-Aug

Review 2.  Diagnosis and Management of Inherited Palmoplantar Keratodermas.

Authors:  Bjorn R Thomas; Edel A O'Toole
Journal:  Acta Derm Venereol       Date:  2020-03-25       Impact factor: 3.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.